Mavorixafor (also called AMD11070) is a small molecule that is a selective and orally bioavailable antagonist of CXCR4 [163] in Phase 1b/2a development in association with immune checkpoint inhibitors in melanoma (NCT02823405) and renal cancer (NCT02923531). This evidence concerns the gene CXCR4 and renal carcinoma.